Diabetologia

---
name: diabetologia
description: Use when targeting Diabetologia or deciding whether a diabetes clinical, epidemiological, or basic/translational study fits this venue. Encodes the journal's diabetes-focused fit across the evidence spectrum, the mechanistic and methodological bar, reporting-guideline and registration requirements, EASD house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.
---

# Diabetologia (diabetologia)

## Journal positioning

Diabetologia is the flagship journal of the European Association for the Study of
Diabetes (EASD), publishing **diabetes-focused research across the full evidence
spectrum** — clinical and pragmatic trials, epidemiology and population science, and
basic/translational science of islet biology, insulin action, complications, and
metabolism. Unlike a broad endocrine journal, Diabetologia is diabetes-dedicated and
explicitly welcomes rigorous basic and mechanistic science (beta-cell biology, insulin
signaling, animal/cell models) alongside human clinical and epidemiologic work. Its
defining expectation is a **significant advance in understanding, preventing, treating,
or explaining diabetes and its complications**, not a small descriptive series or an
association study with no mechanistic or clinical payoff. This skill is a **fit /
venue-selection / re-framing** aid; it is not clinical or regulatory advice and does not
replace the journal's current instructions for authors. Before submitting, re-check the
live Diabetologia author instructions.

## When to trigger

- The author names Diabetologia for a diabetes clinical, epidemiological, or basic/translational
  study and wants a fit/framing check.
- A diabetes study must be re-framed around a mechanism, a prevention/treatment question, or
  a complications-outcome question.
- The author is choosing between Diabetologia (diabetes-specific, incl. basic science), JCEM
  (broad endocrine), and The Lancet Diabetes & Endocrinology (high-impact trials).
- The author needs the journal's reporting-guideline, registration, and basic/animal-study
  expectations for diabetes research.

## Scope & topic fit

- Type 1 and type 2 diabetes: pathogenesis, prevention, glucose-lowering therapy, and
  management trials.
- Diabetes epidemiology and population science: incidence, risk factors, and outcomes across
  cohorts.
- Islet and beta-cell biology, insulin secretion and action, and metabolic mechanism in cells
  and animal models.
- Diabetic complications: nephropathy, retinopathy, neuropathy, and cardiovascular disease in
  diabetes, with mechanism or outcome rigor.
- Gestational diabetes, monogenic diabetes, and metabolic phenotyping studies.
- Diabetes biomarkers, genetics/genomics, and -omics with disease relevance and validation.

## Method & evidence bar

- Clinical studies must be adequately powered with prespecified, patient-centered diabetes
  endpoints; trials require prospective registration and the registration number.
- The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE
  for observational/epidemiologic work, PRISMA for systematic reviews, ARRIVE for animal studies.
- Basic/translational work needs rigorous controls, biological replication, validated
  reagents/models, and blinded/randomized animal experiments where applicable.
- Mechanistic claims require perturbation evidence and, where feasible, anchoring to human
  islets, tissue, or cohorts; glucose/insulin-clamp and metabolic methods must be described.
- Epidemiologic claims must address confounding, bias, and generalizability; causal language
  must match the design.
- Effect estimates need confidence intervals and absolute as well as relative measures.

## Structure & house style

- EASD/Springer format with a structured abstract (aims/hypothesis, methods, results,
  conclusions) and a research-in-context/significance statement; re-check current article
  types and limits on the live guide.
- The introduction frames the diabetes-biology or clinical gap; the discussion states the
  mechanistic or practice implication and bounds overreach.
- A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal
  work reports ARRIVE-aligned detail.
- Figures show representative data with statistics, N, and replication; an electronic
  supplement carries full methods, the protocol/SAP, and additional experiments.

## Official-submission checklist

- Before giving submission-ready advice, read `../../resources/source-basis.md` and
  `../../resources/official-source-map.md`; start from the ICMJE/EQUATOR and EASD/Springer
  anchors, then cite the current Diabetologia page you checked.
- Search the live site for "Diabetologia EASD instructions for authors" and follow the
  current version.
- Re-check article types, abstract structure and research-in-context format, and
  word/figure/reference limits.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE),
  data/code-availability, and protocol/SAP submission.
- Re-check IRB/ethics and consent, animal-care/IACUC approval, ICMJE authorship and
  conflict-of-interest disclosure, funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions
  win.

## Pre-submission self-check

- [ ] The study delivers a clear diabetes mechanism, prevention/treatment, or complications advance.
- [ ] Clinical diabetes endpoints are prespecified and powered; trials are registered with the number in the manuscript.
- [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached.
- [ ] Basic/translational work shows controls, replication, model validation, and human anchoring.
- [ ] Epidemiologic claims address confounding and generalizability; causal language matches the design.
- [ ] IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared.

## Common desk-reject triggers

- Small descriptive diabetes series or registry slice with no mechanism and no clinical payoff.
- Association-only biomarker/-omics studies with no validation cohort or functional follow-up.
- Animal/cell diabetes work without human relevance, replication, or ARRIVE-aligned rigor.
- Missing trial registration, protocol, or the required reporting checklist.
- Broad endocrine scope diluting the diabetes focus, better placed in a generalist endocrine venue.

## Re-routing decision

- Broad endocrine (thyroid/adrenal/bone/reproductive) beyond diabetes → `journal-of-clinical-endocrinology-and-metabolism`.
- High-impact diabetes/endocrine trial with broad reach → `the-lancet-diabetes-and-endocrinology`.
- Diabetic kidney disease centered on nephrology mechanism/outcomes → `journal-of-the-american-society-of-nephrology` / `kidney-international`.
- Obstetric/gestational-diabetes pregnancy outcomes → `american-journal-of-obstetrics-and-gynecology`.
- Broad practice-changing diabetes trial → general medicine (`jama` / NEJM / The Lancet in the natural-science bundle).

## Output format

```text
[Fit] High / Medium / Low (one-line reason)
[Target] Diabetologia (EASD)
[Specialty tags] <T1D / T2D / islet biology / complications / epidemiology + clinical/basic>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / animal-ARRIVE>
[Method/evidence] <power, mechanism, controls/replication, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / IACUC / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
```